 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...190191192193194195196197198199200...235236» |
- | Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly
New P2 trial, Combination therapy, Metastases: Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial. (clinicaltrials.gov) - Jun 1, 2017
P2, N=43, Not yet recruiting, Sponsor: AIO-Studien-gGmbH
- | EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
Trial primary completion date, IO biomarker, Metastases: Anti-CD3 x Anti-Erbitux (clinicaltrials.gov) - May 31, 2017
P1, N=30, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Trial primary completion date: Jul 2016 --> Jan 2019
- ||||| New P1/2 trial: QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors (clinicaltrials.gov) - May 30, 2017
P1/2, N=85, Not yet recruiting, Sponsor: NantCell, Inc.
- ||||| New P1/2 trial: QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy (clinicaltrials.gov) - May 30, 2017
P1/2, N=113, Not yet recruiting, Sponsor: NantCell, Inc.
- ||||| New P1/2 trial: QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC (clinicaltrials.gov) - May 30, 2017
P1/2, N=79, Not yet recruiting, Sponsor: NantCell, Inc.
- ||||| ETBX-061 / ImmunityBio, NK92-CD16-158V / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
New P1/2 trial: QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL (clinicaltrials.gov) - May 30, 2017
P1/2, N=67, Not yet recruiting, Sponsor: NantCell, Inc.
- | oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date: Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas (clinicaltrials.gov) - May 30, 2017
P2, N=34, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jul 2016 --> Jan 2019 Trial primary completion date: Jun 2018 --> Jun 2019
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
New P2 trial, Metastases: Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma (clinicaltrials.gov) - May 30, 2017
P2, N=45, Recruiting, Sponsor: Peking University
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Biomarker, Trial completion, Enrollment change, Trial primary completion date, Metastases: Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - May 25, 2017
P1, N=7, Completed, Sponsor: Mayo Clinic
Trial primary completion date: Jun 2018 --> Jun 2019 Active, not recruiting --> Completed | N=70 --> 7 | Trial primary completion date: Jun 2016 --> Nov 2010
- | New P2 trial, Surgery: A Study of Administering FOLFIRINOX Before Surgery For Potentially Curable Pancreatic Cancer (clinicaltrials.gov) - May 25, 2017
P2, N=20, Not yet recruiting, Sponsor: Petr Kavan
- ||||| New P1/2 trial: QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy (clinicaltrials.gov) - May 25, 2017
P1/2, N=67, Not yet recruiting, Sponsor: NantCell, Inc.
- ||||| New P1/2 trial: QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy (clinicaltrials.gov) - May 25, 2017
P1/2, N=67, Not yet recruiting, Sponsor: NantCell, Inc.
- |||| epacadostat (INCB024360) / Incyte
Enrollment open, Metastases: A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) (clinicaltrials.gov) - May 24, 2017
P1/2, N=332, Recruiting, Sponsor: Incyte Corporation
Active, not recruiting --> Completed | N=70 --> 7 | Trial primary completion date: Jun 2016 --> Nov 2010 Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy, Metastases: A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients (clinicaltrials.gov) - May 23, 2017
P1, N=45, Active, not recruiting, Sponsor: University of Chicago
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2017 --> Apr 2018
- | New P3 trial, Metastases: FOHAIC-1: Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - May 23, 2017
P3, N=130, Recruiting, Sponsor: Sun Yat-sen University
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
New P2 trial: SULTAN: Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network (clinicaltrials.gov) - May 23, 2017
P2, N=140, Not yet recruiting, Sponsor: UNICANCER
- | New P2 trial: FOLOXIRIREC: FOLFOXIRI Chemotherapy Alone as Neoadjuvant Treatment for Circumferential Radial Margin (CRM) Positive Rectal Cancer (clinicaltrials.gov) - May 22, 2017
P2, N=32, Not yet recruiting, Sponsor: Guangxi Medical University
- |||| IMM-101 / Immodulon
Enrollment open, Trial initiation date, Trial primary completion date: Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer (clinicaltrials.gov) - May 22, 2017
P1/2, N=300, Recruiting, Sponsor: Immodulon Therapeutics Ltd
Trial primary completion date: Apr 2017 --> Apr 2018 Not yet recruiting --> Recruiting | Initiation date: Jan 2017 --> May 2017 | Trial primary completion date: Jan 2019 --> May 2019
- | Stivarga (regorafenib) / Bayer
Enrollment closed, Enrollment change, Trial primary completion date: Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX (clinicaltrials.gov) - May 19, 2017
P2, N=24, Active, not recruiting, Sponsor: US Oncology Research
Not yet recruiting --> Recruiting | Initiation date: Jan 2017 --> May 2017 | Trial primary completion date: Jan 2019 --> May 2019 Recruiting --> Active, not recruiting | N=264 --> 24 | Trial primary completion date: Mar 2017 --> Aug 2017
- | oxaliplatin / Generic mfg., capecitabine / Generic mfg.
Enrollment open, Combination therapy, Metastases: IV Ascorbic Acid in Advanced Gastric Cancer (clinicaltrials.gov) - May 18, 2017
P3, N=200, Recruiting, Sponsor: Sun Yat-sen University
Recruiting --> Active, not recruiting | N=264 --> 24 | Trial primary completion date: Mar 2017 --> Aug 2017 Not yet recruiting --> Recruiting
- ||| palupiprant (AN0025) / Eisai, Adlai Nortye
New P1 trial, Combination therapy: PRAER 1: Preoperative Radiotherapy and E7046 in Rectum Cancer (clinicaltrials.gov) - May 15, 2017
P1b, N=68, Not yet recruiting, Sponsor: Eisai Inc.
- || Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Trial primary completion date, Combination therapy, Metastases: Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors (clinicaltrials.gov) - May 12, 2017
P1, N=60, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Trial primary completion date: May 2018 --> Jul 2019
- | Avastin (bevacizumab) / Roche
Enrollment change, Combination therapy, Metastases: FABLOx: Study of 5-fluorouracil (5-FU), Nab (clinicaltrials.gov) - May 12, 2017
P1/2, N=11, Recruiting, Sponsor: Celgene
Trial primary completion date: May 2018 --> Jul 2019 N=84 --> 11
- | 5-fluorouracil / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer (clinicaltrials.gov) - May 11, 2017
P1, N=12, Active, not recruiting, Sponsor: Virginia Commonwealth University
N=84 --> 11 Enrolling by invitation --> Active, not recruiting | N=20 --> 12 | Trial primary completion date: Dec 2017 --> May 2017
- | Cyramza (ramucirumab) / Eli Lilly
Enrollment open, Metastases: RAMIRIS: Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy (clinicaltrials.gov) - May 11, 2017
P2, N=111, Recruiting, Sponsor: Krankenhaus Nordwest
Enrolling by invitation --> Active, not recruiting | N=20 --> 12 | Trial primary completion date: Dec 2017 --> May 2017 Not yet recruiting --> Recruiting
- | oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Enrollment open, Phase classification, Trial initiation date, Trial primary completion date, Surgery, Metastases: Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - May 11, 2017
P, N=8, Recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Phase classification: PN/A --> P | Initiation date: Oct 2016 --> Mar 2017 | Trial primary completion date: Aug 2020 --> Jan 2018
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: DREXNECK: Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer (clinicaltrials.gov) - May 9, 2017
P2, N=1, Completed, Sponsor: Drexel University College of Medicine
Not yet recruiting --> Recruiting | Phase classification: PN/A --> P | Initiation date: Oct 2016 --> Mar 2017 | Trial primary completion date: Aug 2020 --> Jan 2018 N=25 --> 1
- | Enrollment change, Trial withdrawal, Metastases: Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN) (clinicaltrials.gov) - May 9, 2017
P2, N=0, Withdrawn, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=25 --> 1 N=162 --> 0 | Not yet recruiting --> Withdrawn
- |||||| Avastin (bevacizumab) / Roche
Enrollment open, Trial initiation date, Trial primary completion date, Head-to-Head, Surgery: CAIRO6: Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (clinicaltrials.gov) - May 9, 2017
P2/3, N=358, Recruiting, Sponsor: Catharina Ziekenhuis Eindhoven
N=162 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting | Initiation date: Jan 2017 --> May 2017 | Trial primary completion date: Jan 2024 --> Aug 2024
- | Erbitux (cetuximab) / Eli Lilly
Trial completion, Metastases: CEBIFOX: Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer (clinicaltrials.gov) - May 8, 2017
P2, N=59, Completed, Sponsor: Martin Schuler, Prof. Dr. med.
Not yet recruiting --> Recruiting | Initiation date: Jan 2017 --> May 2017 | Trial primary completion date: Jan 2024 --> Aug 2024 Active, not recruiting --> Completed
- | Zolinza (vorinostat) / Merck (MSD), Decadron (dexamethasone) / Merck (MSD), Oncaspar liquid (pegaspargase) / Servier
Trial initiation date: Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I (clinicaltrials.gov) - May 5, 2017
P1/2, N=50, Recruiting, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed Initiation date: Oct 2015 --> Jan 2016
- | Trial initiation date, Trial primary completion date: PROMENADE: Proactive Management of Endoperitoneal Spread in Colonic Cancer (clinicaltrials.gov) - May 5, 2017
P3, N=140, Not yet recruiting, Sponsor: University of Roma La Sapienza
Initiation date: Oct 2015 --> Jan 2016 Initiation date: Mar 2017 --> Sep 2017 | Trial primary completion date: Sep 2021 --> Mar 2022
- ||||| Vectibix (panitumumab) / Amgen
New P2 trial: OPALO: FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status (clinicaltrials.gov) - May 5, 2017
P2, N=80, Not yet recruiting, Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo
- | dactinomycin / Generic mfg.
Enrollment closed, Trial primary completion date: Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia (clinicaltrials.gov) - May 3, 2017
P3, N=384, Active, not recruiting, Sponsor: Gynecologic Oncology Group
Initiation date: Mar 2017 --> Sep 2017 | Trial primary completion date: Sep 2021 --> Mar 2022 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> May 2018
- | Phase classification, Metastases: Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer (clinicaltrials.gov) - May 3, 2017
P4, N=36, Recruiting, Sponsor: University of Chicago
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> May 2018 Phase classification: P1 --> P4
- |||| Bavencio (avelumab) / EMD Serono
Trial primary completion date, Metastases: Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) (clinicaltrials.gov) - May 2, 2017
P3, N=666, Recruiting, Sponsor: EMD Serono Research & Development Institute, Inc.
Phase classification: P1 --> P4 Trial primary completion date: Nov 2018 --> Mar 2019
- ||||| New P1/2 trial: QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (clinicaltrials.gov) - May 1, 2017
P1/2, N=80, Not yet recruiting, Sponsor: NantCell, Inc.
- | Enrollment closed, Surgery: Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine") (clinicaltrials.gov) - May 1, 2017
P2, N=130, Active, not recruiting, Sponsor: Medical College of Wisconsin
Trial primary completion date: Nov 2018 --> Mar 2019 Recruiting --> Active, not recruiting
- | Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
Enrollment closed: FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 28, 2017
P2, N=25, Active, not recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | alisertib (MLN8237) / Puma
Enrollment closed, Combination therapy: Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors (clinicaltrials.gov) - Apr 28, 2017
P1, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | branebrutinib (BMS-986195) / BMS
New P1 trial: Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin (clinicaltrials.gov) - Apr 27, 2017
P1, N=12, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Biomarker, Trial primary completion date, Gene Expression Profile: A Prospective Study of Pharmacogenetic Factors and Gene Expression Profile (clinicaltrials.gov) - Apr 26, 2017
P=N/A, N=2660, Recruiting, Sponsor: Samsung Medical Center
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2013 --> Dec 2017
- |||| vanucizumab (RG7221) / Roche, Avastin (bevacizumab) / Roche
Trial completion, Metastases: McCAVE: A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 26, 2017
P2, N=200, Completed, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jun 2013 --> Dec 2017 Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, LEAC-102 / Taiwan Bio
Trial initiation date, Combination therapy, Metastases: LEAC-102 for Advanced Colorectal Cancer (clinicaltrials.gov) - Apr 26, 2017
P1/2, N=30, Not yet recruiting, Sponsor: Taiwan Leader Biotech Corp.
Active, not recruiting --> Completed Initiation date: Feb 2017 --> Jun 2017
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
New P4 trial: The Efficacy of Silymarin as Adjuvant Therapy on Colorectal Cancer Patients Undergoing FOLFIRI Treatment (clinicaltrials.gov) - Apr 26, 2017
P4, N=50, Recruiting, Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
- | varlitinib (ASLAN001) / ASLAN Pharma
New P2/3 trial, Combination therapy, Metastases: Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line) (clinicaltrials.gov) - Apr 26, 2017
P2/3, N=40, Not yet recruiting, Sponsor: Aslan Pharmaceuticals
- | oxaliplatin / Generic mfg.
Journal: Systemic capillary leak syndrome in a patient receiving adjuvant oxaliplatin for locally advanced colon cancer. (Pubmed Central) - Apr 26, 2017
Documenting future cases of SCLS attributed to oxaliplatin is vital, as SCLS is associated with significant morbidity and mortality and no standard treatments beyond supportive care measures exist. Early recognition and diagnosis are therefore essential to improving patient outcomes.
- || Vectibix (panitumumab) / Amgen
Trial primary completion date, HEOR: SILQ: ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line (clinicaltrials.gov) - Apr 25, 2017
P=N/A, N=300, Recruiting, Sponsor: Amgen
Early recognition and diagnosis are therefore essential to improving patient outcomes. Trial primary completion date: Jun 2018 --> Dec 2019
- ||| pegvorhyaluronidase alfa (PEGPH20) / Halozyme
Enrollment closed, Metastases: S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 24, 2017
P1/2, N=172, Active, not recruiting, Sponsor: Southwest Oncology Group
Trial primary completion date: Jun 2018 --> Dec 2019 Recruiting --> Active, not recruiting
- |||||||||| EndoTAG-1 (paclitaxel liposomal) / Sinphar Pharma
New P3 trial, Metastases: EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX (clinicaltrials.gov) - Apr 24, 2017
P3, N=214, Not yet recruiting, Sponsor: SynCore Biotechnology Co., Ltd.